Group Art Unit No.: 1624

## Amendment to the Claims:

This listing of claims will replace all prior versions and listing of claims in the application:

## **Listing of Claims:**

1-48 (Cancelled).

49. (Currently amended): A compound of Formula I:

$$(R^3)_k$$
 $(CR^6R^7)_m$ 
 $(CR^4R^5)_n$ 
 $(CR^8R^9)_q$ 
 $(CR^8R^9)_q$ 

I

wherein:

X is selected from  $C_1$ - $C_8$  alkyl, halo,  $-OR^{10}$ ,  $-NR^{14}R^{15}$ , nitro, cyano,  $-COOR^{10}$ ,  $-COR^{13}$ ,  $-OCOR^{13}$ ,  $-N(R^{17})COR^{13}$ ,  $-N(R^{17})CONR^{14}R^{15}$ ,  $-N(R^{17})COOR^{13}$ ,  $-SO_3H$ ,  $-SO_2NR^{14}R^{15}$ ,  $-C(=NR^{17})NR^{14}R^{15}$ ,  $-N(R^{17})SO_2R^{16}$ , and a 5 or 6-membered heterocyclic group;

or X and an adjacent R<sup>3</sup>, taken together with the atoms to which they are bonded, form an alkylenedioxy moiety;

Z is CH,  $CR^3$  or N, wherein when Z is CH or  $CR^3$ , k is 0-4 and t is 0 or 1, and when Z is N, k is 0-3 and t is 0;

Y is selected from -O-, -S-, -N( $R^{10}$ )-, and -C( $R^4$ )( $R^5$ )-;

 $W^1 \text{ is selected from $C_1$-$C_6$ alkyl, $C_3$-$C_8$ cycloalkyl, aryl and Het, wherein said $C_1$-$C_8$ alkyl, $C_3$-$C_8$ cycloalkyl, aryl and Het are optionally unsubstituted or substituted with one or more groups independently selected from halo, cyano, nitro, $C_1$-$C_6$ alkyl, $C_3$-$C_6$ alkenyl, $C_3$-$C_6$ alkynyl, $-C_0$-$C_6$ alkyl-$CO_2$R^{10}$, $-C_0$-$C_6$ alkyl-$C(O)SR^{10}$, $-C_0$-$C_6$ alkyl-$CONR^{11}R^{12}$, $-C_0$-$C_6$ alkyl-$COR^{13}$, $-C_0$-$C_6$ alkyl-$NR^{11}R^{12}$, $-C_0$-$C_6$ alkyl-$SR^{10}$, $-C_0$-$C_6$ alkyl-$SO_3$H, $-C_0$-$C_6$ alkyl-$SO_2$NR^{11}R^{12}$, $-C_0$-$C_6$ alkyl-$SO_2$R^{10}$, $-C_0$-$C_6$ alkyl-$SO_2$R^{10}$, $-C_0$-$C_6$ alkyl-$SOR^{13}$, $-C_0$-$C_6$ alkyl-$OC(O)NR^{11}R^{12}$, $-C_0$-$C_6$ alkyl-$OC(O)NR^{11}R^{12}$, and$ 

Group Art Unit No.: 1624

-C<sub>0</sub>-C<sub>6</sub> alkyl-NR<sup>11</sup>COR<sup>13</sup>, where said C<sub>1</sub>-C<sub>6</sub> alkyl, is optionally unsubstituted or substituted by one or more halo substituents;

W<sup>2</sup> is selected from H, halo, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl,  $-C_0-C_6$  alkyl-NR<sup>11</sup>R<sup>12</sup>,  $-C_0-C_6$  alkyl-SR<sup>10</sup>,  $-C_0-C_6$  alkyl-OR<sup>10</sup>,  $-C_0-C_6$  alkyl-CO<sub>2</sub>R<sup>10</sup>,  $-C_0-C_6$  alkyl-C(O)SR<sup>10</sup>,  $-C_0-C_6$  alkyl-CONR<sup>11</sup>R<sup>12</sup>,  $-C_0-C_6$  alkyl-COR<sup>13</sup>,  $-C_0-C_6$  alkyl-OCOR<sup>13</sup>,  $-C_0-C_6$  alkyl-OCONR<sup>11</sup>R<sup>12</sup>,  $-C_0-C_6$  alkyl-NR<sup>11</sup>CONR<sup>11</sup>R<sup>12</sup>, -C<sub>0</sub>-C<sub>6</sub> alkyl-NR<sup>11</sup>COR<sup>13</sup>, -C<sub>0</sub>-C<sub>6</sub> alkyl-Het, -C<sub>0</sub>-C<sub>6</sub> alkyl-aryl and -C<sub>0</sub>-C<sub>6</sub> alkyl-C<sub>3</sub>-C<sub>7</sub> cycloalkyl, wherein said C<sub>1</sub>-C<sub>6</sub> alkyl is optionally unsubstituted or substituted by one or more halo substituents, and wherein the C<sub>3</sub>-C<sub>7</sub> cycloalkyl, aryl and Het moieties of said -C<sub>0</sub>-C<sub>6</sub> alkyl-Het, -C<sub>0</sub>-C<sub>6</sub> alkyl-aryl and -C<sub>0</sub>-C<sub>6</sub> alkyl-C<sub>3</sub>-C<sub>7</sub> cycloalkyl are optionally unsubstituted or substituted with one or more groups independently selected from halo, cyano, nitro, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>3</sub>-C<sub>6</sub> alkenyl, C<sub>3</sub>-C<sub>6</sub> alkynyl, -C<sub>0</sub>-C<sub>6</sub> alkyl-CO<sub>2</sub>R<sup>10</sup>,  $-C_0-C_6$  alkyl-C(O)SR<sup>10</sup>,  $-C_0-C_6$  alkyl-CONR<sup>11</sup>R<sup>12</sup>,  $-C_0-C_6$  alkyl-COR<sup>13</sup>,  $-C_0-C_6$  alkyl-NR<sup>11</sup>R<sup>12</sup>, -C<sub>0</sub>-C<sub>6</sub> alkyl-SR<sup>10</sup>, -C<sub>0</sub>-C<sub>6</sub> alkyl-OR<sup>10</sup>, -C<sub>0</sub>-C<sub>6</sub> alkyl-SO<sub>3</sub>H, -C<sub>0</sub>-C<sub>6</sub> alkyl-SO<sub>2</sub>NR<sup>11</sup>R<sup>12</sup>,  $-C_0-C_6$  alkyl- $SO_7R^{10}$ ,  $-C_0-C_6$  alkyl- $SOR^{13}$ ,  $-C_0-C_6$  alkyl- $OCOR^{13}$ , -C<sub>0</sub>-C<sub>6</sub> alkyl-OC(O)NR<sup>11</sup>R<sup>12</sup>, -C<sub>0</sub>-C<sub>6</sub> alkyl-OC(O)OR<sup>13</sup>, -C<sub>0</sub>-C<sub>6</sub> alkyl-NR<sup>11</sup>C(O)OR<sup>13</sup>, -C<sub>0</sub>-C<sub>6</sub> alkyl-NR<sup>11</sup>C(O)NR<sup>11</sup>R<sup>12</sup>, and -C<sub>0</sub>-C<sub>6</sub> alkyl-NR<sup>11</sup>COR<sup>13</sup>, where said C<sub>1</sub>-C<sub>6</sub> alkyl, is optionally unsubstituted or substituted by one or more halo substituents;

 $W^3$  is selected from the group consisting of: H, halo,  $C_1$ - $C_6$  alkyl,  $-C_0$ - $C_6$  alkyl- $NR^{11}R^{12}$ ,  $-C_0$ - $C_6$  alkyl- $SR^{10}$ ,  $-C_0$ - $C_6$  alkyl- $OR^{10}$ ,  $-C_0$ - $C_6$  alkyl- $CO_2R^{10}$ ,  $-C_0$ - $C_6$  alkyl- $CO_2R^{11}R^{12}$ ,  $-C_0$ - $C_6$  alkyl- $CO_2R^{11}R^{12}$ ,  $-C_0$ - $C_6$  alkyl- $CO_2R^{11}R^{12}$ ,  $-C_0$ - $C_0$  alkyl- $CO_2R^{11}R^{12}$ ,  $-C_0$ - $CO_2R^{11}R^{12}$ ,  $-C_0$ - $-C_0$  alkyl- $-CO_2R^{11}R^{12}$ ,  $-C_0$ - $-C_0$  alkyl- $-CO_2R^{11}R^{12}$ ,  $-C_0$ - $-C_0$  alkyl- $-CO_0$  alkyl- $-CO_0$ 

Q is selected from  $C_3$ - $C_8$  cycloalkyl, Ar and Het; wherein said  $C_3$ - $C_8$  cycloalkyl, Ar and Het are optionally unsubstituted or substituted with one or more groups independently selected from halo, cyano, nitro,  $C_1$ - $C_6$  alkyl,  $C_3$ - $C_6$  alkenyl,  $C_3$ - $C_6$  alkyl- $C_0$ - $C_0$ 

Group Art Unit No.: 1624

 $-C_0-C_6$  alkyl-NR<sup>11</sup>C(O)NR<sup>11</sup>R<sup>12</sup>, and  $-C_0-C_6$  alkyl-NR<sup>11</sup>COR<sup>13</sup>, where said  $C_1-C_6$  alkyl is optionally unsubstituted or substituted by one or more halo substituents;

p is 0-8; n is 3; m is 0 or 1; q is 0 or 1; t is 0 or 1;

each  $R^1$  and  $R^2$  are independently selected from H, halo,  $C_1$ - $C_6$  alkyl,  $C_3$ - $C_6$  alkenyl,  $C_3$ - $C_6$  alkyl- $NR^{11}R^{12}$ ,  $-C_0$ - $C_6$  alkyl- $OR^{10}$ ,  $-C_0$ - $C_6$  alkyl- $SR^{10}$ ,  $-C_1$ - $C_6$  alkyl-Het,  $-C_1$ - $C_6$  alkyl-Ar and  $-C_1$ - $C_6$  alkyl- $C_3$ - $C_7$  cycloalkyl, or  $R^1$  and  $R^2$  together with the carbon to which they are attached form a 3-5 membered carbocyclic or heterocyclic ring, wherein said heterocyclic ring contains one, or more heteroatoms selected from N, O, and S, where any of said  $C_1$ - $C_6$  alkyl is optionally unsubstituted or substituted by one or more halo substituents;

each R<sup>3</sup> is the same or different and is independently selected from halo, cyano, nitro,

 $C_1$ - $C_6$  alkyl,  $C_3$ - $C_6$  alkenyl,  $C_3$ - $C_6$  alkyl-Ar,  $-C_0$ - $C_6$  alkyl-Het,

-C<sub>0</sub>-C<sub>6</sub> alkyl-C<sub>3</sub>-C<sub>7</sub> cycloalkyl, -C<sub>0</sub>-C<sub>6</sub> alkyl-CO<sub>2</sub>R<sup>10</sup>, -C<sub>0</sub>-C<sub>6</sub> alkyl-C(O)SR<sup>10</sup>,

 $-C_0-C_6 \ alkyl-CONR^{11}R^{12}, \ -C_0-C_6 \ alkyl-COR^{13}, \ -C_0-C_6 \ alkyl-NR^{11}R^{12}, \ -C_0-C_6 \ alkyl-SR^{10}, \ -C_0-C_6 \ al$ 

 $-C_0-C_6 \ alkyl-OR^{10}, \ -C_0-C_6 \ alkyl-SO_3H, \ -C_0-C_6 \ alkyl-SO_2NR^{11}R^{12}, \ -C_0-C_6 \ alkyl-SO_2R^{10}, \$ 

 $-C_0-C_6 \ alkyl-SOR^{13}, \ -C_0-C_6 \ alkyl-OCOR^{13}, \ -C_0-C_6 \ alkyl-OC(O)NR^{11}R^{12}, \\$ 

 $-C_0-C_6 \ alkyl-OC(O)OR^{13}, \ -C_0-C_6 \ alkyl-NR^{11}C(O)OR^{13}, \ -C_0-C_6 \ alkyl-NR^{11}C(O)NR^{11}R^{12}, \ and \ -C_0-C_0 \ alkyl-NR^{11}C(O)NR^{11$ 

-C<sub>0</sub>-C<sub>6</sub> alkyl-NR<sup>11</sup>COR<sup>13</sup>, wherein said C<sub>1</sub>-C<sub>6</sub> alkyl is optionally unsubstituted or substituted by one or more halo substituents;

each  $R^4$  and  $R^5$  is independently selected from H, halo,  $C_1$ - $C_6$  alkyl,  $-C_0$ - $C_6$  alkyl-Het,  $-C_0$ - $C_6$  alkyl-Ar and  $-C_0$ - $C_6$  alkyl- $C_3$ - $C_7$  cycloalkyl;

R<sup>6</sup> and R<sup>7</sup> are each independently selected from H, halo, C<sub>1</sub>-C<sub>6</sub> alkyl,

-C0-C6 alkyl-Het, -C0-C6 alkyl-Ar and -C0-C6 alkyl-C3-C7 cycloalkyl;

R<sup>8</sup> and R<sup>9</sup> are each independently selected from H, halo, C<sub>1</sub>-C<sub>6</sub> alkyl,

-C<sub>0</sub>-C<sub>6</sub> alkyl-Het, -C<sub>0</sub>-C<sub>6</sub> alkyl-Ar and -C<sub>0</sub>-C<sub>6</sub> alkyl-C<sub>3</sub>-C<sub>7</sub> cycloalkyl;

 $R^{10}$  is selected from H,  $C_1$ - $C_6$  alkyl,  $C_3$ - $C_6$  alkenyl,  $C_3$ - $C_6$  alkynyl, - $C_0$ - $C_6$  alkyl-Ar,

-C0-C6 alkyl-Het and -C0-C6 alkyl-C3-C7 cycloalkyl;

each  $R^{11}$  and each  $R^{12}$  are independently selected from H,  $C_1$ - $C_6$  alkyl,  $C_3$ - $C_6$  alkenyl,  $C_3$ - $C_6$  alkyl-Ar,  $-C_0$ - $C_6$  alkyl-Het and  $-C_0$ - $C_6$  alkyl- $C_3$ - $C_7$  cycloalkyl, or  $R^{11}$ 

Group Art Unit No.: 1624

and R<sup>12</sup> together with the nitrogen to which they are attached form a 4-7 membered heterocyclic ring which optionally contains one or more additional heteroatoms selected from N, O, and S;

 $R^{13} \ is \ selected \ from \ C_1\text{-}C_6 \ alkyl, \ C_3\text{-}C_6 \ alkenyl, \ C_3\text{-}C_6 \ alkynyl, \ -C_0\text{-}C_6 \ alkyl-Ar,}$   $-C_0\text{-}C_6 \ alkyl-Het \ and \ -C_0\text{-}C_6 \ alkyl-C_3\text{-}C_7 \ cycloalkyl;}$ 

R<sup>14</sup> and R<sup>15</sup> are each independently selected from H, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>3</sub>-C<sub>6</sub> alkenyl, C<sub>3</sub>-C<sub>6</sub> alkynyl, -C<sub>0</sub>-C<sub>6</sub> alkyl-Ar, -C<sub>0</sub>-C<sub>6</sub> alkyl-Het, -C<sub>0</sub>-C<sub>6</sub> alkyl-C<sub>3</sub>-C<sub>7</sub> cycloalkyl, -C<sub>0</sub>-C<sub>6</sub> alkyl-O-Ar, -C<sub>0</sub>-C<sub>6</sub> alkyl-O-Het, -C<sub>0</sub>-C<sub>6</sub> alkyl-O-C<sub>3</sub>-C<sub>7</sub> cycloalkyl,  $-C_0-C_6$  alkyl- $S(O)_x-C_1-C_6$  alkyl,  $-C_0-C_6$  alkyl- $S(O)_x-Ar$ ,  $-C_0-C_6$  alkyl- $S(O)_x-Het$ , -C<sub>0</sub>-C<sub>6</sub> alkyl-S(O)<sub>x</sub>-C<sub>3</sub>-C<sub>7</sub> cycloalkyl, -C<sub>0</sub>-C<sub>6</sub> alkyl-NH-Het, -C<sub>0</sub>-C<sub>6</sub> alkyl-NH- $C_3$ - $C_7$  cycloalkyl,  $-C_0$ - $C_6$  alkyl- $N(C_1$ - $C_4$  alkyl)-Ar,  $-C_0$ - $C_6$  alkyl- $N(C_1$ - $C_4$  alkyl)-Het, -C<sub>0</sub>-C<sub>6</sub> alkyl-N(C<sub>1</sub>-C<sub>4</sub> alkyl)-C<sub>3</sub>-C<sub>7</sub> cycloalkyl, -C<sub>0</sub>-C<sub>6</sub> alkyl-Ar, -C<sub>0</sub>-C<sub>6</sub> alkyl-Het and -C<sub>0</sub>-C<sub>6</sub> alkyl-C<sub>3</sub>-C<sub>7</sub> cycloalkyl, where x is 0, 1 or 2, or R<sup>14</sup> and R<sup>15</sup>, together with the nitrogen to which they are attached, form a 4-7 membered heterocyclic ring which optionally contains one or more additional heteroatoms selected from N, O, and S, wherein said C<sub>1</sub>-C<sub>6</sub> alkyl is optionally substituted by one or more of the substituents independently selected from the group halo, -OH, -SH, -NH<sub>2</sub>, -NH(unsubstituted C<sub>1</sub>-C<sub>6</sub> alkyl), -N(unsubstituted C<sub>1</sub>-C<sub>6</sub> alkyl)(unsubstituted C<sub>1</sub>-C<sub>6</sub> alkyl), unsubstituted -OC<sub>1</sub>-C<sub>6</sub> alkyl, -CO<sub>2</sub>H, -CO<sub>2</sub>(unsubstituted C<sub>1</sub>-C<sub>6</sub> alkyl), -CONH<sub>2</sub>, -CONH(unsubstituted C<sub>1</sub>-C<sub>6</sub> alkyl), -CON(unsubstituted C<sub>1</sub>-C<sub>6</sub> alkyl)(unsubstituted C<sub>1</sub>-C<sub>6</sub> alkyl), -SO<sub>3</sub>H, -SO<sub>2</sub>NH<sub>2</sub>, -SO<sub>2</sub>NH(unsubstituted C<sub>1</sub>-C<sub>6</sub> alkyl) and -SO<sub>2</sub>N(unsubstituted C<sub>1</sub>-C<sub>6</sub> alkyl)(unsubstituted  $C_1$ - $C_6$  alkyl);

 $R^{16}$  is  $C_1$ - $C_6$  alkyl, - $C_0$ - $C_6$  alkyl-Ar or - $C_0$ - $C_6$  alkyl-Het; and  $R^{17}$  is H,  $C_1$ - $C_6$  alkyl, - $C_0$ - $C_6$  alkyl-Ar or - $C_0$ - $C_6$  alkyl-Het;

Group Art Unit No.: 1624

 $-C_0-C_6$  alkyl-C(=NR')NR'R", and  $-C_0-C_6$  alkyl-SO<sub>2</sub>NR'R", wherein each R' and R" are independently selected from H and unsubstituted  $C_1-C_6$  alkyl,

each Het independently represents a 5- to 7-membered, a 7- to 10-membered or an 11to 18-membered tricyclic heterocyclic ring group which is saturated, unsaturated or aromatic,
and consists of carbon atoms and from one to three heteroatoms selected from N, O and S,
wherein the N or S heteroatoms of said Het are optionally oxidized or the N heteroatom is
optionally quaternized, wherein said Het is optionally unsubstituted or substituted by one or
more of the substituents independently selected from the group halo, cyano, C<sub>1</sub>-C<sub>6</sub> alkyl
(which specifically includes C<sub>1</sub>-C<sub>6</sub> haloalkyl, -C<sub>0</sub>-C<sub>6</sub> alkyl-OH, -C<sub>0</sub>-C<sub>6</sub> alkyl-SH and
-C<sub>0</sub>-C<sub>6</sub> alkyl-NR'R"), C<sub>3</sub>-C<sub>6</sub> alkenyl, oxo, -OC<sub>1</sub>-C<sub>6</sub> alkyl, -OC<sub>1</sub>-C<sub>6</sub> alkenyl, -C<sub>0</sub>-C<sub>6</sub> alkyl-COR',
-C<sub>0</sub>-C<sub>6</sub> alkyl-CO<sub>2</sub>R', -C<sub>0</sub>-C<sub>6</sub> alkyl-CONR'R", -OC<sub>0</sub>-C<sub>6</sub> alkyl-CO<sub>2</sub>H, -OC<sub>2</sub>-C<sub>6</sub> alkyl-NR'R",
-C<sub>0</sub>-C<sub>6</sub> alkyl-C(=NR')NR'R" and -C<sub>0</sub>-C<sub>6</sub> alkyl-SO<sub>2</sub>NR'R", wherein each R' and R" are
independently selected from H and unsubstituted C<sub>1</sub>-C<sub>6</sub> alkyl;

provided that X is not COOR<sup>10</sup> when Y is -O-, p is 0-8, n is 3, m is 1, q is 0 or 1, t is 0, each  $R^1$  and  $R^2$  is independently selected from H,  $C_1$ - $C_6$  alkyl, -OH, -O- $C_1$ - $C_6$  alkyl, -SH, and -S- $C_1$ - $C_6$  alkyl, each  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$  and  $R^9$  are independently H or  $C_1$ - $C_4$  alkyl, k is 0 or 1, W<sup>3</sup> is H, W<sup>1</sup> and W<sup>2</sup> are each independently selected from  $C_3$ - $C_8$  cycloalkyl and aryl and  $R^3$  and O are as defined above; or

provided that the compound is not

benzoic acid,

5-[3-[[(3,4-dichlorophenyl)methyl][2-(2-naphthalenyl)ethyl]amino]propoxy]-3-methoxy-1,2-benzenedicarboxylic acid,

5-[3-[[(3,4-dichlorophenyl)methyl][2-(2-naphthalenyl)ethyl]amino]propoxy]-3-methoxy-1,2-benzenedicarboxylic acid, dimethyl ester,
4-[[[2-(4-carboxyphenoxy)ethyl][2-[2-[(5-phenylpentyl)oxy]phenyl]ethyl]amino]methyl]

4-[[[2-[4-(ethoxycarbonyl)phenoxy]ethyl][2-[2-(octyloxy)phenyl]ethyl]amino]methyl]-benzoic acid methyl ester,

4-[[[2-(4-carboxyphenoxy)ethyl][2-[2-(octyloxy)phenyl]ethyl]amino]methyl], benzoic acid,

 $\alpha$ -[[[3-(4-fluorophenyl)-1,1-dimethylpropyl](phenylmethyl)amino]methyl]-3-(phenylmethoxy)-benzenemethanol hydrochloride,

N-[2-(4-amino-3,5-dichlorophenyl)ethyl]-4-fluoro-N-(phenylmethyl)-

Group Art Unit No.: 1624

benzenepropanamine monohydrochloride,

N-[2-(4-amino-3,5-dichlorophenyl)ethyl]-4-chloro-N-(phenylmethyl)-benzenepropanamine monohydrochloride,

4-amino-3,5-dichloro- $\alpha$ -[[[3-(4-fluorophenyl)propyl](phenylmethyl)amino]methyl]-benzenemethanol monohydrochloride,

 $\label{eq:continuous} 4-amino-3,5-dichloro-\alpha-[[[3-(4-chlorophenyl)propyl](phenylmethyl)amino]methyl]-benzenemethanol monohydrochloride,$ 

2-chloro-5-[2-[[3-(4-fluorophenyl)-1-methylpropyl](phenylmethyl)amino]-1-hydroxyethyl]-benzamide monohydrochloride,

4-[2-[[2-hydroxy-2-[4-(phenylmethoxy)phenyl]ethyl](phenylmethyl)amino]ethoxy]-benzeneacetamide,

4-[2-[[2-[3,4-bis(phenylmethoxy)phenyl]ethyl](phenylmethyl)amino]ethoxy]-benzenesulfonamide monohydrochloride,

(R)-3-(phenylmethoxy)- $\alpha$ -[[[3-[3-

(phenylmethoxy) phenyl] propyl] (phenylmethyl) amino] methyl] -benzenemethanol,

2,2-dichloro-acetic acid (R)-{benzyl-[3-(3-benzyloxy-phenyl)-propyl]-amino}-(3-benzyloxy-phenyl)-ethyl ester,

 $3\text{-}amino\text{-}\alpha\text{-}[[[3\text{-}(3,4\text{-}dimethoxyphenyl})\text{-}1\text{-}$ 

methylpropyl](phenylmethyl)amino]methyl]-4-(phenylmethoxy)-benzenemethanol,

 $\alpha$ -[[[3-(3,4-dimethoxyphenyl)-1-methylpropyl](phenylmethyl)amino]methyl]-3-nitro-4-(phenylmethoxy)-benzenemethanol,

 $\alpha$ -[[[3-(3,4-dimethoxyphenyl)-1-methylpropyl](phenylmethyl)amino]methyl]-3-nitro-5-(phenylmethoxy)-benzenemethanol,

3-amino-α-[[[3-(3,4-dimethoxyphenyl)-1-

methyl propyl] (phenyl methyl) a mino] methyl] - 5 - (phenyl methoxy) - benzene methanol, or a methyl propyll (phenyl methyl) - 5 - (phenyl methoxy) - benzene methanol, or a methyl propyll (phenyl methyl) - 5 - (phenyl methoxy) - benzene methanol, or a methyl propyll (phenyl methyl) - 5 - (phenyl methoxy) - benzene methanol, or a methyl propyll (phenyl methyl) - 5 - (phenyl methoxy) - benzene methanol, or a methyl propyll (phenyl methyl) - 5 - (phenyl methoxy) - benzene methanol, or a methyl propyll (phenyl methyl) - 5 - (phenyl methoxy) - benzene methanol, or a methyl propyll (phenyl methyl) - 5 - (phenyl methoxy) - benzene methanol, or a methyl propyll (phenyl methyl) - 5 - (phenyl methoxy) - benzene methanol, or a methyl propyll (phenyl methyl) - 5 - (phenyl methoxy) - benzene methanol, or a methyl propyll (phenyl methyl) - 5 - (phenyl methoxy) - benzene methanol, or a methyl propyll (phenyl methyl) - 5 - (phenyl methyl) - 5 - (phenyl methoxy) - 5 - (phenyl methyl) - (phenyl met

4-[2-[[2-(4-fluorophenoxy)ethyl](phenylmethyl)amino]ethyl]-1-piperazineacetic acid ethyl ester;

or a pharmaceutically acceptable salt or [[solvate]] hydrate thereof.

50. (Previously presented): The compound according to claim 49, wherein p is 0, 1 or 2.

Group Art Unit No.: 1624

51. (Previously presented): The compound according to claim 49, wherein t is 0.

- 52. (Previously presented): The compound according to claim 49, wherein  $R^1$  and  $R^2$  are independently H or  $C_1$ - $C_4$  alkyl or  $R^1$  and  $R^2$  together with the carbon to which they are attached form a 3-5 membered carbocyclic ring.
- 53. (Previously presented): The compound according to claim 49, wherein k is 0 or 1.
- 54. (Previously presented): The compound according to claim 49, wherein  $R^3$  is selected from halo,  $C_1$ - $C_4$  alkyl and  $C_1$ - $C_4$  alkoxy.
- 55. (Previously presented): The compound according to claim 49, wherein X is selected from  $C_1$ - $C_6$  alkyl, halo,  $-OR^{10}$ ,  $-NR^{14}R^{15}$ , cyano,  $-COR^{13}$ ,  $-COOR^{10}$ ,  $-OCOR^{13}$ ,  $-N(R^{17})CONR^{14}R^{15}$ ,  $-N(R^{17})COR^{13}$ ,  $-SO_2NR^{14}R^{15}$ ,  $-N(R^{17})SO_2R^{16}$ , and a 5 or 6-membered heterocyclic group or X and an adjacent  $R^3$ , taken together with the atoms to which they are bonded, form an alkylenedioxy moiety.
- 56. (Previously presented): The compound according to claim 55, wherein R<sup>10</sup> is H, C<sub>1</sub>-C<sub>4</sub> alkyl or phenyl; R<sup>13</sup> is H, C<sub>1</sub>-C<sub>4</sub> alkyl, -C<sub>0</sub>-C<sub>4</sub> alkyl-C<sub>3</sub>-C<sub>7</sub> cycloalkyl, or -C<sub>0</sub>-C<sub>4</sub> alkyl-phenyl; R<sup>14</sup> and R<sup>15</sup> are each independently selected from H, C<sub>1</sub>-C<sub>6</sub> alkyl, -C<sub>0</sub>-C<sub>4</sub> alkyl-Ar, -C<sub>0</sub>-C<sub>4</sub> alkyl-Het, -C<sub>0</sub>-C<sub>4</sub> alkyl-C<sub>3</sub>-C<sub>7</sub> cycloalkyl, -C<sub>0</sub>-C<sub>4</sub> alkyl-O-Ar, -C<sub>0</sub>-C<sub>4</sub> alkyl-O-Het, -C<sub>0</sub>-C<sub>4</sub> alkyl-O-C<sub>3</sub>-C<sub>7</sub> cycloalkyl, -C<sub>0</sub>-C<sub>4</sub> alkyl-S(O)<sub>2</sub>-C<sub>1</sub>-C<sub>4</sub> alkyl, -C<sub>0</sub>-C<sub>4</sub> alkyl-S(O)<sub>2</sub>-Ar, -C<sub>0</sub>-C<sub>4</sub> alkyl-S(O)<sub>2</sub>-Het, -C<sub>0</sub>-C<sub>4</sub> alkyl-S(O)<sub>2</sub>-C<sub>3</sub>-C<sub>7</sub> cycloalkyl, -C<sub>0</sub>-C<sub>4</sub> alkyl-NH-Ar, -C<sub>0</sub>-C<sub>4</sub> alkyl-NH-Het, -C<sub>0</sub>-C<sub>4</sub> alkyl-NH-C<sub>3</sub>-C<sub>7</sub> cycloalkyl, -C<sub>0</sub>-C<sub>4</sub> alkyl-N(C<sub>1</sub>-C<sub>4</sub> alkyl)-Ar, -C<sub>0</sub>-C<sub>4</sub> alkyl-N(C<sub>1</sub>-C<sub>4</sub> alkyl)-Het, -C<sub>0</sub>-C<sub>4</sub> alkyl-N(C<sub>1</sub>-C<sub>4</sub> alkyl)-C<sub>3</sub>-C<sub>7</sub> cycloalkyl, or R<sup>14</sup> and R<sup>15</sup>, together with the nitrogen to which they are attached, form a 4-7 membered heterocyclic ring which optionally contains one or more additional heteroatoms selected from N, O, and S, wherein said C<sub>1</sub>-C<sub>6</sub> alkyl is optionally substituted by one or more of the substituents independently selected from the group halo, -OH, -SH, -NH<sub>2</sub>, -NH(unsubstituted C<sub>1</sub>-C<sub>4</sub> alkyl), -N(unsubstituted C<sub>1</sub>-C<sub>4</sub> alkyl)(unsubstituted

Group Art Unit No.: 1624

 $C_1$ - $C_4$  alkyl), unsubstituted -OC<sub>1</sub>- $C_4$  alkyl, -CO<sub>2</sub>H, -CO<sub>2</sub>(unsubstituted  $C_1$ - $C_4$  alkyl), -CONH<sub>2</sub>, -CONH(unsubstituted  $C_1$ - $C_4$  alkyl), -CON(unsubstituted  $C_1$ - $C_4$  alkyl) (unsubstituted  $C_1$ - $C_4$  alkyl), -SO<sub>3</sub>H, -SO<sub>2</sub>NH<sub>2</sub>, -SO<sub>2</sub>NH(unsubstituted  $C_1$ - $C_4$  alkyl) and -SO<sub>2</sub>N(unsubstituted  $C_1$ - $C_4$  alkyl) (unsubstituted  $C_1$ - $C_4$  alkyl);  $R^{16}$  is  $C_1$ - $C_4$  alkyl or phenyl; and  $R^{17}$  is H or  $C_1$ - $C_4$  alkyl.

- 57. (Previously presented): The compound according to claim 49 wherein each  $R^4$  and  $R^5$  are independently selected from H and  $C_1$ - $C_3$  alkyl.
  - 58. (Previously presented): The compound according to claim 49, wherein q is 1.
- 59. (Previously presented): The compound according to claim 49, wherein  $R^8$  and  $R^9$  are each H.
- 60. (Previously presented): The compound according to claim 49, wherein Q is a substituted or unsubstituted phenyl or furanyl group or a benzo[1,3]dioxyl or benzo[1,4]dioxyl group containing one, two or three substituents selected from halo,  $C_1$ - $C_4$  alkyl;  $C_1$ - $C_4$  alkylthio; or -NR<sup>Q1</sup>R<sup>Q2</sup>, where R<sup>Q1</sup> and R<sup>Q2</sup> taken together with the nitrogen to which they are attached form a 4-7 membered heterocyclic ring, which may optionally contain one or more additional heteroatoms selected form N, O and S.
- 61. (Previously presented): The compound according to claim 60, wherein said substituents are selected from fluoro, chloro, trifluoromethyl, tert-butyl, isopropyl, methylthio and piperidin-1-yl.
- 62. (Previously presented): The compound according to claim 49, wherein m is 0 or m is 1 and  $R^6$  and  $R^7$  are each H.
- 63. (Previously presented): The compound according to claim 49, wherein W<sup>1</sup> is phenyl, naphthyl, thienyl, pyridyl, furanyl, pyrrolyl, cyclohexyl, cyclopentyl, morpholinyl, or pyrrolidinyl, where each phenyl, naphthyl, thienyl, pyridyl, furanyl, pyrrolyl, cyclohexyl, cyclopentyl, morpholinyl, or pyrrolidinyl may be optionally substituted from 1 to 3 times with

Group Art Unit No.: 1624

one or more of the substituents independently selected from  $C_1$ - $C_4$  alkyl, -OH, halo, -O- $C_1$ - $C_4$  alkyl, and - $C_1$ - $C_4$  haloalkyl.

64. (Previously presented): The compound according to claim 49, wherein  $W^2$  is  $C_1$ - $C_4$  alkyl,  $C_2$ - $C_4$  alkynyl,  $C_3$ - $C_6$  cycloalkyl, aryl, Het hydroxy, aryloxy-,  $C_1$ - $C_4$  alkoxy-,  $-OCOC_1$ - $C_4$  alkyl, -OCOaryl, or  $-NR^{W1}R^{W2}$ , where  $R^{W1}$  and  $R^{W2}$  are independently H or  $C_1$ - $C_4$  alkyl or taken together with the nitrogen to which they are attached form a 4-7 membered heterocyclic ring, which may optionally contain one or more additional heteroatoms selected form N, O and S.

65. (Withdrawn): The compound according to claim 49, wherein  $W^3$  is H or  $C_1$ - $C_4$  alkyl.

66. (Previously presented): The compound according to claim 49, wherein X is selected from C<sub>1</sub>-C<sub>6</sub> alkyl, halo, -OR<sup>10</sup>, -NR<sup>14</sup>R<sup>15</sup>, cyano, -COR<sup>13</sup>, -COOR<sup>10</sup>, -OCOR<sup>13</sup>,  $-N(R^{17})CONR^{14}R^{15}$ ,  $-N(R^{17})COR^{13}$ ,  $-SO_2NR^{14}R^{15}$ ,  $-N(R^{17})SO_2R^{16}$ , and a 5 or 6-membered heterocyclic group or X and an adjacent R<sup>3</sup>, taken together with the atoms to which they are bonded, form an alkylenedioxy moiety, where R<sup>10</sup> is H, C<sub>1</sub>-C<sub>4</sub> alkyl or phenyl, R<sup>13</sup> is H,  $C_1\text{-}C_4 \text{ alkyl, -}C_0\text{-}C_4 \text{ alkyl-}C_3\text{-}C_7 \text{ cycloalkyl, or -}C_0\text{-}C_4 \text{ alkyl-phenyl, } R^{14} \text{ and } R^{15} \text{ are each } R^{14} \text{ and } R^{15} \text{ are each } R^{14} \text{ and } R^{15} \text{ are each } R$ independently selected from H, C<sub>1</sub>-C<sub>6</sub> alkyl, -C<sub>0</sub>-C<sub>4</sub> alkyl-Ar, -C<sub>0</sub>-C<sub>4</sub> alkyl-Het, -C<sub>0</sub>-C<sub>4</sub> alkyl-C<sub>3</sub>-C<sub>7</sub> cycloalkyl, -C<sub>0</sub>-C<sub>4</sub> alkyl-O-Ar, -C<sub>0</sub>-C<sub>4</sub> alkyl-O-Het,  $-C_0-C_4$  alkyl $-O-C_3-C_7$  cycloalkyl,  $-C_0-C_4$  alkyl $-S(O)_2-C_1-C_4$  alkyl,  $-C_0-C_4$  alkyl $-S(O)_2-Ar$ ,  $-C_0-C_4$  alkyl-S(O)<sub>2</sub>-Het,  $-C_0-C_4$  alkyl-S(O)<sub>2</sub>-C<sub>3</sub>-C<sub>7</sub> cycloalkyl,  $-C_0-C_4$  alkyl-NH-Ar,  $-C_0-C_4$  alkyl-NH-Het,  $-C_0-C_4$  alkyl-NH- $-C_3-C_7$  cycloalkyl,  $-C_0-C_4$  alkyl-N( $-C_1-C_4$  alkyl)-Ar,  $-C_0-C_4 \text{ alkyl-} N(C_1-C_4 \text{ alkyl})-\text{Het, } -C_0-C_4 \text{ alkyl-} N(C_1-C_4 \text{ alkyl})-C_3-C_7 \text{ cycloalkyl, }$ -C<sub>0</sub>-C<sub>4</sub> alkyl-Ar, -C<sub>0</sub>-C<sub>4</sub> alkyl-Het and -C<sub>0</sub>-C<sub>4</sub> alkyl-C<sub>3</sub>-C<sub>7</sub> cycloalkyl, or R<sup>14</sup> and R<sup>15</sup>, together with the nitrogen to which they are attached, form a 4-7 membered heterocyclic ring which optionally contains one or more additional heteroatoms selected from N, O, and S, wherein said C<sub>1</sub>-C<sub>6</sub> alkyl is optionally substituted by one or more of the substituents independently selected from the group halo, -OH, -SH, -NH<sub>2</sub>, -NH(unsubstituted C<sub>1</sub>-C<sub>4</sub> alkyl), -N(unsubstituted C<sub>1</sub>-C<sub>4</sub> alkyl)(unsubstituted C<sub>1</sub>-C<sub>4</sub> alkyl), unsubstituted -OC<sub>1</sub>-C<sub>4</sub> alkyl, -CO<sub>2</sub>H, -CO<sub>2</sub>(unsubstituted C<sub>1</sub>-C<sub>4</sub> alkyl), -CONH<sub>2</sub>, -CONH(unsubstituted C<sub>1</sub>-C<sub>4</sub> alkyl),

Group Art Unit No.: 1624

-CON(unsubstituted C<sub>1</sub>-C<sub>4</sub> alkyl)(unsubstituted C<sub>1</sub>-C<sub>4</sub> alkyl), -SO<sub>3</sub>H, -SO<sub>2</sub>NH<sub>2</sub>, -SO<sub>2</sub>NH(unsubstituted C<sub>1</sub>-C<sub>4</sub> alkyl) and -SO<sub>2</sub>N(unsubstituted C<sub>1</sub>-C<sub>4</sub> alkyl)(unsubstituted  $C_1$ - $C_4$  alkyl),  $R^{16}$  is  $C_1$ - $C_4$  alkyl or phenyl, and  $R^{17}$  is H or  $C_1$ - $C_4$  alkyl; p is 0, 1 or 2;  $R^1$  and R<sup>2</sup> are independently H or C<sub>1</sub>-C<sub>4</sub> alkyl or R<sup>1</sup> and R<sup>2</sup> together with the carbon to which they are attached form a 3-5 membered carbocyclic ring; k is 0 or k is 1 and R<sup>3</sup> is halo, C<sub>1</sub>-C<sub>4</sub> alkyl or  $C_1$ - $C_4$  alkoxy; n is 3 and each  $R^4$  and  $R^5$  are independently selected from H and  $C_1$ - $C_3$  alkyl; Z is CH or N: Y is -O- or -C( $\mathbb{R}^4$ )( $\mathbb{R}^5$ )-; q is 1;  $\mathbb{R}^8$  and  $\mathbb{R}^9$  are each H; Q is a substituted or unsubstituted phenyl or furanyl group or a benzo[1,3]dioxyl or benzo[1,4]dioxyl group, where the substituted phenyl or furanyl group contains one, two or three substituents selected from halo, C<sub>1</sub>-C<sub>4</sub> alkyl; C<sub>1</sub>-C<sub>4</sub> alkylthio; or -NR<sup>Q1</sup>R<sup>Q2</sup>, where R<sup>Q1</sup> and R<sup>Q2</sup> taken together with the nitrogen to which they are attached form a 4-7 membered heterocyclic ring, which may optionally contain one or more additional heteroatoms selected form N, O and S; t is 0 or 1; m is 0 or 1;  $R^6$  and  $R^7$  are independently selected from H and  $C_1$ - $C_4$  alkyl;  $W^1$  is methyl, unsubstituted phenyl, naphthyl, pyridyl, thienyl or pyrrolyl or substituted phenyl or pyridyl containing one or two substituents independently selected from halo, alkyl and alkoxy, specifically, chloro, methyl and methoxy; W<sup>2</sup> is C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>2</sub>-C<sub>4</sub> alkynyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, aryl, Het hydroxy, aryloxy-, C<sub>1</sub>-C<sub>4</sub> alkoxy-, -OCOC<sub>1</sub>-C<sub>4</sub> alkyl, -OCOaryl, or -NR<sup>W1</sup>R<sup>W2</sup>, where RW1 and RW2 are independently H or C1-C4 alkyl or taken together with the nitrogen to which they are attached form a 4-7 membered heterocyclic ring, which may optionally contain one or more additional heteroatoms selected form N, O and S; W3 is H or C1-C4 alkyl; or a pharmaceutically acceptable salt or solvate thereof.

Group Art Unit No.: 1624

```
-morpholin-4-yl, -thiomorpholin-4-yl, -piperidin-1-yl, -piperidin-1-yl-(4-carboxylic acid),
-piperidin-1-yl-(4-acetic acid), -piperidin-4-yl-(1-acetic acid), -2,5-dimethyl-pyrrol-1-yl,
-pyrrolidin-1-yl, -((R)-2-CO<sub>2</sub>H-pyrrolidin-1-yl), -((S)-2-CO<sub>2</sub>H-pyrrolidin-1-yl),
-piperazin-1-yl, -(4-methyl-piperazin-1-yl), -piperazin-1-yl-(4-acetic acid),
-NHCH<sub>2</sub>-(5-bromo-thien-2-yl), -NHCH<sub>2</sub>-1H-imidazol-2-yl,
-NHCH<sub>2</sub>-(1-methyl-imidazol-2-yl, -NHCOCH<sub>3</sub>, -N(CH<sub>3</sub>)COCH<sub>3</sub>, -NHCO<sub>2</sub>C(CH<sub>3</sub>)<sub>3</sub>,
-NHCOCH_2CH_3, -NHCOC(CH_3)_2, -NHCO-furan-2-yl, -N(CH_3)CO-furan-2-yl, -N(CH_3)CO-furan-
-NHCO-thien-2-yl, -NHCO-cyclopropyl, -NHCO-(5-bromo-thien-2-yl,
-NHCO-(2,5-dimethyl-pyrrol-3-yl), -NHSO<sub>2</sub>CH<sub>3</sub>, -N(CH<sub>3</sub>)SO<sub>2</sub>CH<sub>3</sub>, -NHSO<sub>2</sub>CF<sub>3</sub>,
-NHSO<sub>2</sub>phenyl, -N(CH<sub>3</sub>)SO<sub>2</sub>phenyl, -NHSO<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, -NHSO<sub>2</sub>CH<sub>2</sub>CF<sub>3</sub>,
-NHSO<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, -NHSO<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>,-NHCONH(2-chlorophenyl),
-N(CH<sub>3</sub>)CONH(3,5-dimethoxyphenyl), -N(CH<sub>3</sub>)CONH(2-chlorophenyl),
-N(CH_3)CO-(benzo[1,3]diox-5-yl), -SO_2NHCH_3, and -SO_2N(CH_3)_2; \ p \ is \ 0, \ 1 \ or \ 2; \ R^1 \ and \ R^2
are H C1-C4 alkyl or R1 and R2 together with the carbon to which they are attached form a 3, 4
or 5 membered carbocyclic ring; Z is CH or N; k is 0 or k is 1 and R<sup>3</sup> is methyl,
trifluoromethyl, chloro or methoxy; n is 3 and R<sup>4</sup> and R<sup>5</sup> are independently selected from H
and methyl: Y is -O- or -C(\mathbb{R}^4)(\mathbb{R}^5)-; q is 1; \mathbb{R}^8 and \mathbb{R}^9 are each H; Q is
2-chloro-3-(trifluoromethyl)phenyl, 3-methyl-4-fluoro-phenyl, 4-tert-butyl-phenyl,
4-(methylthio)phenyl, 2,4,5-trifluoro-phenyl, 4-isopropyl-phenyl,
5-(piperidin-1-vl)-furan-2-vl, benzo[1,3]diox-5-yl, or 2,3-dihydrobenzo[1,4]dioxin-6-yl; t is
0 or 1; m is 0 or 1; R<sup>6</sup> and R<sup>7</sup> are independently selected from H and methyl; W<sup>1</sup> is methyl,
phenyl, naphth-1-yl, pyrid-2-yl, 4-methyl-pyrid-2-yl, thien-2-yl, thien-3-yl, pyrrol-2-yl,
2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2-methoxyphenyl, or 4-methoxyphenyl; W<sup>2</sup>
is methyl, ethyl, ethynyl, isopropyl, n-butyl, 2-methylpropyl, trifluorormethyl, cyclohexyl,
unsubstituted phenyl, hydroxy, methoxy, phenoxy, dimethylamino, morpholin-4-yl,
```

Claims 68-69 (Cancelled).

acceptable salt or solvate thereof.

phenylcarbonyloxy, or methylcarbonyloxy; W<sup>3</sup> is H or methyl; or a pharmaceutically

Group Art Unit No.: 1624

70. (Withdrawn): The compound according to claim 49, wherein  $W^1$  and  $W^2$  are not each independently  $C_3$ - $C_8$  cycloalkyl or aryl or  $W^3$  is not H or any one of  $R^6$  or  $R^7$  is not H or  $R^8$  and  $R^9$  are each  $C_1$ - $C_4$  alkyl when:

X is COOR<sup>10</sup>;

Z is CH or CR<sup>3</sup> and k is 0-4 or Z is N and k is 0-3;

p is 0-8;

n is 3;

q is 0 or 1;

Q is selected from optionally unsubstituted or substituted  $C_3$ - $C_8$  cycloalkyl, phenyl and monocyclic Het;

each  $R^1$  and  $R^2$  is independently selected from H,  $C_1$ - $C_6$  alkyl, -OH, -O- $C_1$ - $C_6$  alkyl, -SH, and -S- $C_1$ - $C_6$  alkyl; and

each  $R^3$  is the same or different and is independently selected from halo, cyano, nitro,  $-CONR^{12}R^{13}$ ,  $-COR^{14}$ ,  $-SR^{11}$ ,  $-SO_2R^{11}$ ,  $-SO_2R^{14}$ ,  $-OCOR^{14}$  and optionally unsubstituted or substituted  $C_1$ - $C_6$  alkyl,  $C_3$ - $C_6$  alkenyl, -5-6 membered-Het,  $-C_0$ - $C_6$  alkyl- $-CO_2R^{11}$ , or  $-C_0$ - $-C_6$  alkyl- $-NR^{12}R^{13}$ .

71. (Currently amended): A pharmaceutical composition comprising [[a]] the compound according to claim 49 and a pharmaceutically acceptable carrier or diluent.

Claims 72-91 (Cancelled).

- 92. (Withdrawn): A method for the prevention or treatment of an LXR mediated disease or condition, wherein said disease or condition is selected from atherosclerosis and inflammation, comprising administering a therapeutically effective amount of the compound according to claim 49.
- 93. (Withdrawn): The method according to claim 92, comprising administering a therapeutically effective amount of the compound according to claim 52.

Group Art Unit No.: 1624

94. (Withdrawn): The method according to claim 92, comprising administering a therapeutically effective amount of the compound according to claim 55.

- 95. (Withdrawn): The method according to claim 92, comprising administering a therapeutically effective amount of the compound according to claim 56.
- 96. (Withdrawn): The method according to claim 92, comprising administering a therapeutically effective amount of the compound according to claim 57.
- 97. (Withdrawn): The method according to claim 92, comprising administering a therapeutically effective amount of the compound according to claim 60.
- 98. (Withdrawn): The method according to claim 92, comprising administering a therapeutically effective amount of the compound according to claim 63.
- 99. (Withdrawn): The method according to claim 92, comprising administering a therapeutically effective amount of the compound according to claim 64.
- 100. (Withdrawn): The method according to claim 92, comprising administering a therapeutically effective amount of the compound according to claim 66.
- 101. (Withdrawn): The method according to claim 92, comprising administering a therapeutically effective amount of the compound according to claim 67.
- 102. (Withdrawn, Currently amended): The method according to claim 92, comprising administering a compound selected from:
- 2-(3-{3-[[2-chloro-3-(trifluoromethyl)benzyl](2,2-dephenylethyl)amino]propoxy}phenyl)-ethanol,
- (2-chloro-3-trifluoromethyl-benzyl)-(2,2-diphenylethyl)-{3-[3-(1,2,4-triazol-3-ylmethyl)-phenoxy]-propyl}-amine,
- (2-chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-{3-[3-(1,2,3,4-tetrazol-5-ylmethyl)-phenoxy]-propyl}-amine,

Group Art Unit No.: 1624

- (S)-(2-chloro-3-trifluoromethyl-benzyl)-(2-phenyl-propyl)-{3-[3-(1,2,3,4-tetrazol-3-ylmethyl)-phenoxy]-propyl}-amine,
- (R)-(2-chloro-3-trifluoromethyl-benzyl)-(2-phenyl-propyl)-{3-[3-(1,2,3,4-tetrazol-3-ylmethyl)-phenoxy]-propyl}-amine,
- (S)-2-(3-{3-[[2-chloro-3-(trifluoromethyl)benzyl](2-phenyl-propyl)amino]propoxy}-phenyl)acetic acid,
- (*R*)-2-(3-{3-[[2-chloro-3-(trifluoromethyl)benzyl](2-phenyl-propyl)amino]propoxy}-phenyl)acetic acid,
- 2-(3-{3-[[2-chloro-3-(trifluoromethyl)benzyl](2-acetoxy-2-phenyl-ethyl)amino]propoxy}-phenyl)acetic acid,
- (3-{3-[(2-acetoxy-2-phenyl-ethyl)-(2-chloro-3-trifluoromethyl-benzyl)-amino]-propoxy}-phenyl)-acetic acid methyl ester,
- (3-{4-[(2-chloro-3-(trifluoromethyl)benzyl)-(2,2-diphenylethyl)-amino]butyl}phenyl)-acetic acid,
- 1-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-phenyl)-cyclobutanecarboxylic acid,
- N-(2,2-diphenylethyl)-N-(2-chloro-3-trifluoromethylbenzyl)-3-(3-[2-hydroxy-2-methylpropyl]phenoxy)propylamine,
- (2-chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-[3-(3-{2-[(1H-imidazol-2-ylmethyl)-amino] -ethyl}-phenoxy)-propyl]-amine,
- N-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-2,2-diphenylethyl-amino]-propoxy}-phenyl)-methanesulfonamide,
- N-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-2,2-diphenylethyl-amino]-propoxy}-phenyl)-N-methyl-amine,
- [2-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-phenyl)-ethylamino]-acetic acid,
- (R)-1-[2-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-phenyl)-ethyl]-pyrrolidine-2-carboxylic acid,
- furan-2-carboxylic acid N-(3-{3-{(2-chloro-3-trifluoromethyl-benzyl)-2,2-diphenylethyl-amino}-propoxy}-phenyl)-amide,
- N-(2-[3-chlorophenyl]-propyl)-N-(2-chloro-3-trifluoromethylbenzyl)-3-(3-carboxymethylenephenoxy) propylamine,

Group Art Unit No.: 1624

(2-chloro-3-trifluoromethyl-benzyl)-{3-[3-(2-morpholin-4-yl-ethyl)-phenoxy]-propyl}-((S)-2-phenyl-propyl amine,

[4-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-phenyl)-piperazin-1-yl]-acetic acid,

2-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-((S)-2-phenyl-propyl)-amino]-propoxy}-phenyl)-2-methyl-propionic acid,

(2-chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-{3-[3-(4-methyl-piperazin-1-yl)-phenoxy]-propyl}-amine,

(3-{(R)-3-[(2-chloro-3-trifluoromethyl-benzyl)-((S)-2-phenyl-propyl)-amino]-butoxy}-phenyl)-acetic acid,

[1-(3-{3-[(2-chloro-3-(trifluoromethyl)-benzyl)-(2,2-diphenylethyl)-amino]-propoxy}-phenyl-piperidine-4-carboxylic acid,

[4-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-((S)-2-phenyl-propyl)-amino]-propoxy}-phenyl)-piperazin-1-yl]-acetic acid,

[4-(3-{(R)-[(2-chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-methyl-propoxy}-phenyl)-piperazin-1-yl]-acetic acid,

and a stereoisomer, a stereoisomeric mixture or racemate thereof and a pharmaceutically acceptable salt or [[solvate]] <a href="https://example.com/hydrate">hydrate</a> thereof.

- 103. (Withdrawn): A method for increasing reverse cholesterol transport, said method comprising administering a therapeutically effective amount of the compound according to claim 49.
- 104. (Withdrawn): A method for inhibiting cholesterol absorption, said method comprising administering a therapeutically effective amount of the compound according to claim 49.

105. (New): A compound selected from:

2-(3-{3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-dephenylethyl)amino]propoxy}phenyl)-ethanol; 2-(3-{3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]propoxy}-phenyl)acetic acid, N-oxide; (3-{3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]propoxy}-bromobenzene;

Group Art Unit No.: 1624

(4-{3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]propoxy}bromobenzene; (2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenylethyl)-{3-[3-(1,2,4-triazol-3-ylmethyl)-phenoxyl-propyl}-amine; (2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenylethyl)-{3-[3-(1,2,3,4-tetrazol-5-vlmethyl)-phenoxyl-propyl}-amine; (2-Chloro-3 $trifluoromethyl-benzyl)-(2-cyclohexyl-2-phenyl-ethyl)-\{3-[3-(1,2,3,4-tetrazol-5-ylmethyl)-(2-cyclohexyl-2-phenyl-ethyl)-(3-[3-(1,2,3,4-tetrazol-5-ylmethyl)-(3-[3-(1,2,3,4-t$ phenoxy]-propyl}-amine; (S)-(2-Chloro-3-trifluoromethyl-benzyl)-(2-phenyl-propyl)-{3-[3-(1,2,3,4-tetrazol-3-ylmethyl)-phenoxyl-propyl}-amine; (R)-(2-Chloro-3-trifluoromethylbenzyl)-(2-phenyl-propyl)-{3-[3-(1,2,3,4-tetrazol-3-ylmethyl)-phenoxyl-propyl}-amine; (S)-2-(3-{3-[[2-Chloro-3-(trifluoromethyl)benzyl](2-phenyl-propyl)amino]propoxy}phenyl)acetic acid; (R)-2-(3-{3-[[2-Chloro-3-(trifluoromethyl)benzyl](2-phenylpropyl)amino\propoxy\-phenyl)acetic acid; 2-(3-{3-[[2-Chloro-3-(trifluoromethyl)benzyl] naphthalen-1-ylmethyl-amino]propoxy}-phenyl)acetic acid; 2-(3-[3-[2-Chloro-3-(trifluoromethyl)benzyl]-benzylamino]propoxy}-phenyl)acetic acid; 2-(3-{3-[2-Chloro-3-(trifluoromethyl)-benzyl]phenethylamino]propoxy}-phenyl)acetic acid; 2-(3-{3-[[2-Chloro-3-(trifluoromethyl)benzyl](2-hydroxy-2-phenyl-ethyl)amino]propoxy}-phenyl)acetic acid; 2-(3-{3-[[2-Chloro-3-(trifluoromethyl)benzyl](2-acetoxy-2-phenyl-ethyl)amino]propoxy}phenyl)acetic acid; 2-(3-{3-[[2-chloro-3-(trifluoromethyl)benzyl](2-phenoxy-2-phenylethyl)amino|propoxy}-phenyl)acetic acid; Benzoic acid 2-[3-(3-carboxymethyl-phenoxy){2chloro-3-(trifluoromethyl)benzyl}propylamino]-1-phenyl ethyl ester; (3-{3-[(2-Acetoxy-2phenyl-ethyl)-(2-chloro-3-trifluoromethyl-benzyl)-aminol-propoxy}-phenyl)-acetic acid methyl ester; Benzoic acid 2-[3-(3-methoxycarbonylmethyl-phenoxy){2-chloro-3-(trifluoromethyl)benzyl}propylamino]-1-phenyl ethyl ester; (3-{4-[(2-Chloro-3-(trifluoromethyl)benzyl)-(2,2-diphenylethyl)-amino]butyl}phenyl)-acetic acid; (3-{3-[(4-Fluoro-3-methyl-benzyl)-((R)-2-phenyl-propyl)-amino]-propoxy}-phenyl)-acetic acid; (3-{3-[Benzo[1,3]dioxol-5-ylmethyl-((R)-2-phenyl-propyl)-amino]-propoxy}-phenyl)-acetic acid; (3-{3-[(4-tert-Butyl-benzyl)-((R)-2-phenyl-propyl)-amino]-propoxy}-phenyl)-acetic acid; (3-{3-[(2,3-Dihydro-benzo[1,4]dioxin-6-ylmethyl)-((R)-2-phenyl-propyl)-amino]-propoxy}phenyl)-acetic acid; (3-{3-[(4-Methylsulfanyl-benzyl)-((R)-2-phenyl-propyl)-amino]propoxy}-phenyl)-acetic acid; (3-{3-[((R)-2-Phenyl-propyl)-(2,4,5-trifluoro-benzyl)-amino]propoxy}-phenyl)-acetic acid; (3-{3-{((R)-2-Phenyl-propyl)-(5-piperidin-1-yl-furan-2ylmethyl)-amino]-propoxy}-phenyl)-acetic acid; (3-{3-[(4-Isopropyl-benzyl)-((R)-2-phenylpropyl)-amino]-propoxy}-phenyl)-acetic acid; 2-(3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-

Group Art Unit No.: 1624

diphenylethyl-amino]-propoxy}-phenyl)-propane-1,3-diol; N-(3-{3-[(2-Chloro-3trifluoromethyl-benzyl)-2,2-diphenylethyl-aminol-propoxy}-phenyl)-carbamic acid tert-butyl ester; 3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-2,2-diphenylethylamino]-propoxy}phenylamine; N-(3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-2,2-diphenylethyl-amino]propoxy}-phenyl)-acetamide; Furan-2-carboxylic acid N-(3-{3-[(2-Chloro-3-trifluoromethylbenzyl)-2,2-diphenylethyl-amino]-propoxy}-phenyl)-amide; N-(3-{3-[(2-Chloro-3trifluoromethyl-benzyl)-2,2-diphenylethyl-aminol-propoxy}-phenyl)-methanesulfonamide; N-(3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-2,2-diphenylethyl-amino]-propoxy}-phenyl)benzenesulfonamide; 1-(2-Chloro-phenyl)-3-(3-[(2-chloro-3-trifluoromethyl-benzyl)-2,2diphenylethyl-amino]-propoxy}-phenyl)-urea; N-(3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-2,2-diphenylethyl-amino]-propoxy}-phenyl)-N-methyl-amine; N-(3-{3-[(2-Chloro-3trifluoromethyl-benzyl)-2,2-diphenylethyl-amino]-propoxy}-phenyl)-N-methyl-acetamide; Furan-2-carboxylic acid N-(3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-2,2-diphenylethylamino]-propoxy}-phenyl)-N-methyl-amide; N-(3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-2,2-diphenylethyl-amino]-propoxy}-phenyl)-N-methyl-methanesulfonamide; (3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-2,2-diphenylethyl-amino]-propoxy}-phenyl)-N-methylbenzenesulfonamide; 3-(2-Chloro-phenyl)-1-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-2,2diphenylethyl-amino]-propoxy}-phenyl)-1-methyl-urea; Benzo[1,3]dioxole-5-carboxylic acid N-(3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-2,2-diphenylethyl-amino]-propoxy}-phenyl)-Nmethyl-amide; 1-(3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-2,2-diphenylethyl-amino]propoxy}-phenyl)-3-(3,5-dimethoxy-phenyl)-1-methyl-urea; Propane-1-sulfonic acid (5-{3-[(2-chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-2-methyl-phenyl)amide; 3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-2-methylphenylamine; 2-Chloro-5-{3-[(2-chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]propoxy}-phenylamine; 3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)amino]-propoxy}-phenyl)-cyclopentyl-amine; (3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-amino]-propoxy}-phenyl)-isopropyl-amine; Chloro-3-trifluoromethylbenzyl)-(2,2-diphenyl-ethyl)-amino]-propoxy}-phenyl)-ethyl-amine; (3-{3-[(2-Chloro-3trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-amino]-propoxy}-phenyl)-(3-methyl-butyl)amine; (3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-phenyl)isobutyl-amine; (3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-amino]propoxy}-phenyl)-(2,2,2-trifluoroethyl)-amine; (3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-

Group Art Unit No.: 1624

(2,2-diphenyl-ethyl)-amino]-propoxy}-phenyl)-cyclopropylmethy-l-amine; (3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-aminol-propoxy}-phenyl)-(2-ethyl-butyl)amine; (3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-amino]-propoxy}phenyl)-(2,2-dimethyl-propyl)-amine; (3-{3-{(2-Chloro-3-trifluoromethyl-benzyl)-(2,2diphenyl-ethyl)-amino]-propoxy}-phenyl)-hexyl-amine; Butyl-(3-{3-{(2-chloro-3trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-amino]-propoxy}-phenyl)-amine; [1-(3-{3-[(2-Chloro-3-(trifluoromethyl)-benzyl)-(2,2-diphenylethyl)-amino]-propoxy}-phenyl-piperidine-4-carboxylic acid; [1-(3-{3-[(2-Chloro-3-(trifluoromethyl)-benzyl)-(2,2-diphenylethyl)amino]-propoxy}-phenyl-piperidine-4-yl-acetic acid; [4-(3-{3-[(2-Chloro-3-(trifluoromethyl)benzyl)-(2,2-diphenylethyl-amino]-propoxy}-phenyl)-piperidin-1-yl]-acetic acid; rac-±-(3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-(trifluoro-phenyl-propyl)-amino]-propoxy}-phenyl)acetic acid; rac-±-(3-{3-{(2-Chloro-3-trifluoromethyl-benzyl)-(2-dimethylamino-2-phenylethyl)-amino]-propoxy}-phenyl)-acetic acid; rac-±-(3-{3-[(2-Chloro-3-trifluoromethylbenzyl)-(2-morpholin-4-yl-2-phenyl-ethyl)-aminol-propoxy}-phenyl)-acetic acid; (2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-[3-(6-morpholin-4-yl-pyridin-2-yloxy)propyl]-amine; [3-(6-Chloro-pyridin-2-yloxy)-propyl]-(2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-amine; (2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-{3-[6-(4-methyl-piperazin-1-yl)-pyridin-2-yloxy]-propyl}-amine; (2-Chloro-3-trifluoromethylbenzyl)-(2,2-diphenyl-ethyl)-[3-(6-piperazin-1-yl-pyridin-2-yloxy)-propyl]-amine; [4-(6-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)- amino]-propoxy}-pyridin-2-yl)piperazin-1-yl]-acetic acid; 2-(3-{3-[[2-Chloro-3-(trifluoromethyl)benzyl]((S)-2-phenylpropyl)amino]- (R)-1-methyl-propoxy}-phenyl)acetic acid; 2-(3-[3-[[2-Chloro-3-(trifluoromethyl)benzyl]((S)-2-phenyl-propyl)amino]-(R)-1-methyl-propoxy}-phenyl) ethanol; 2-(3-{3-[[2-Chloro-3-(trifluoromethyl)benzyl]((S)-2-phenyl-propyl)amino]-(R)-2methyl-propoxy}-phenyl)acetic acid; 2-(3-{3-[[2-Chloro-3-(trifluoromethyl)benzyl]((S)-2phenyl-propyl)amino]- (R)-2-methyl-propoxy}-phenyl) ethanol; 2-(3-{3-[[2-Chloro-3-(trifluoromethyl)benzyll((R)-2-phenyl-propyl)aminol-(R)-2-methyl-propoxyl-phenyl)acetic acid; 2-(3-{3-[[2-Chloro-3-(trifluoromethyl)benzyl]((R)-2-phenyl-propyl)amino]-(R)-2methyl-propoxy}-phenyl)ethanol; (R)-2-(3-[3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2diphenylethyl)amino]-2-methyl-propoxy}-phenyl)ethanol; 3-{3-[(3-Chloro-2-trifluoromethylbenzyl)-diphenylethyl-aminol-propoxy-N,N-dimethyl-benzenesulfonamide; Cyclopropanecarboxylic acid 3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-diphenylethyl-

Group Art Unit No.: 1624

amino]-propoxy}-benzylamide; N -(3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-diphenylethylamino]-propoxy}-benzyl)-isobutyramide; Acetic acid (3-{3-[(2-chloro-3-trifluoromethylbenzyl)-diphenylethyl-amino]-propoxy}-benzylcarbamoyl)-methyl ester; N- -(3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-diphenylethyl-aminol-propoxy}-benzyl)-propionamide; 2,5-Dimethyl-2-H -pyrazole-3-carboxylic acid 3-{3-[(2-chloro-3-trifluoromethyl-benzyl)diphenylethyl-amino]-propoxy}-benzylamide; (2-Chloro-3-trifluoromethyl-benzyl)-(2,2diphenyl-ethyl)-(3-o-tolyloxy-propyl)-amine; 2-{3-[(2-Chloro-3-trifluoromethyl-benzyl)diphenylethyl-amino]-propoxy}-benzonitrile; 3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)diphenylethyl-amino]-propoxy}-benzonitrile; [3-(3-Chloro-phenoxy)-propyl]-(2-chloro-3trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-amine; (2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-[3-(2-methoxy-phenoxy)-propyl]-amine; [3-(2-Chloro-phenoxy)-propyl]-(2-chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-amine; (2-Chloro-3-trifluoromethylbenzyl)-(2,2-diphenyl-ethyl)-(3-phenoxy-propyl)-amine; (2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-[3-(3-isopropyl-phenoxy)-propyl]-amine; (2-Chloro-3-trifluoromethylbenzyl)-(2,2-diphenyl-ethyl)-[3-(4-methoxy-phenoxy)-propyl]-amine; 3-{3-[(Chlorotrifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-phenol; 2-{3-[(Chlorotrifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-phenol; 3-{3-[(Chlorotrifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-phenylamine; (2-Chloro-3trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-[3-(3-trifluoromethyl-phenoxy)-propyl]-amine; 1-(3-{3-[(Chloro-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-phenyl)-ethanone; (3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-phenyl-phenylamine; [3-(Benzo[1,3]dioxol-5-yloxy)-propyl]-(2-chloro-3-trifluoromethyl-benzyl)-(2,2diphenyl-ethyl)-amine; (2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-(3-mtolyloxy-propyl)-amine; (2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-[3-(3methoxy-phenoxy)-propyl]-amine; (2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-[3-(3-isobutyl-phenoxy)-propyl]-amine; [3-(3-Butyl-phenoxy)-propyl]-(2-chloro-3trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-amine; (2-Chloro-3-trifluoromethyl-benzyl)-{3-[3-(2,2-dimethyl-propyl)-phenoxyl-propyl}-(2,2-diphenyl-ethyl)-amine; (4-{3-[(2-Chloro-3trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-benzyl)-methyl-amine; (2-Chloro-3trifluoromethyl-benzyl)-[3-(4-dimethylaminomethyl-phenoxy)-propyl]-(2,2-diphenyl-ethyl)amine; (2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-[3-(4-morpholin-4-ylmethylphenoxy)-propyl]-amine; (2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-{3-[4-(4-

Group Art Unit No.: 1624

methyl-piperazin-1-ylmethyl)-phenoxyl-propyl}-amine; (3-{3-[(Chloro-trifluoromethylbenzyl)-diphenylethyl-amino]-propoxy}-benzyl)-methyl-amine; (2-Chloro-3-trifluoromethylbenzyl)-[3-(3-dimethylaminomethyl-phenoxy)-propyl]-(2,2-diphenyl-ethyl)-amine; (2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-[3-(3-morpholin-4-ylmethyl-phenoxy)propyl]-amine; (2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-{3-[3-(4-methylpiperazin-1-ylmethyl)-phenoxyl-propyl}-amine; (3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)diphenylethyl-amino]-propoxy}-benzyl)-isopropyl-amine; {3-[(2-Chloro-3-trifluoromethylbenzyl)-(2,2-diphenyl-ethyl-amino)]-propoxy}-4-trifluoromethyl-phenylamine; {3-[(2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl-amino)]-propoxy}-4-methylphenylamine; Ethanesulfonic acid (3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-(2,2-diphenylethyl-amino)]-propoxy}-4-methyl-phenyl)-amide; Propane-2-sulfonic acid (3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl-amino)]-propoxy}-4-methyl-phenyl)-amide; Methanesulfonic acid (3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethylamino)]-propoxy}-4-methyl-phenyl)-amide; 2,2,2-Trifluoro-ethanesulfonic acid (3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl-amino)]-propoxy}-4-methyl-phenyl)amide; Ethanesulfonic acid (3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethylamino)]-propoxy}-phenyl)-amide; 2,2,2-Trifluoro-ethanesulfonic acid (3-{3-[(2-Chloro-3trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl-amino)]-propoxy}-phenyl)-amide; N-(3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl-amino)]-propoxy}-phenyl)-1,1,1trifluoro-methanesulfonamide; Propane-2-sulfonic acid (3-{3-[(2-Chloro-3-trifluoromethylbenzyl)-(2,2-diphenyl-ethyl-amino)]-propoxy}-phenyl)-amide; {3-[(2-Chloro-3trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl-amino)]-propoxy}-4-methoxy-phenylamine; Ethanesulfonic acid (3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl-amino)]propoxy}-4-methoxy-phenyl)-amide; (2-Chloro-3-trifluoromethyl-benzyl)-{3-[3-(2morpholin-4-yl-ethyl)-phenoxy]-propyl}-((S)-2-phenyl-propyl amine; (2-Chloro-3trifluoromethyl-benzyl)-{3-[3-(2-ethylamino-ethyl)-phenoxy]-propyl}-((S)-2-phenyl-propyl)amine; (3-{(R)-3-[(2-Chloro-3-trifluoromethyl-benzyl)-((S)-2-phenyl-propyl)-amino]butoxy}-phenyl)-acetic acid; (3-{(S)-3-[(2-Chloro-3-trifluoromethyl-benzyl)-((S)-2-phenylpropyl)-amino]-butoxy}-phenyl)-acetic acid; 2-(3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-((S)-2-phenyl-propyl)-aminol-propoxy}-phenyl)-ethanol; 2-(3-{3-[(2-Chloro-3trifluoromethyl-benzyl)-((S)-2-phenyl-propyl)-amino]-propoxy}-phenyl)-2-methyl-propionic acid; 2-(3-{3-{(2-Chloro-3-trifluoromethyl-benzyl)-((R)-2-phenyl-propyl)-amino}-propoxy}-

Group Art Unit No.: 1624

phenyl)-2-methyl-propionic acid; (3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-(2-thiophen-3yl-propyl)-amino]-propoxy}-phenyl)-acetic acid; 2-(3-{3-[(2-Chloro-3-trifluoromethylbenzyl)-(2-thiophen-3-yl-propyl)-amino]-propoxy}-phenyl)-ethanol; (3-{3-[(2-Chloro-3trifluoromethyl-benzyl)-(2-thiophen-2-yl-propyl)-aminol-propoxy}-phenyl)-acetic acid; (3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-(2-pyridin-2-yl-propyl)-amino]-propoxy}-phenyl)acetic acid; [3-(3-{(2-Chloro-3-trifluoromethyl-benzyl)-[2-(4-methyl-pyridin-2-yl)-propyl]amino}-propoxy)-phenyl]-acetic acid; [3-(3-{(2-Chloro-3-trifluoromethyl-benzyl)-[3,3,3trifluoro-2-(1H -pyrrol-2-yl)-propyl]-amino}-propoxy) -phenyl]-acetic acid; (2-Chloro-3trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-(3-{3-[2-(4-methyl-piperazin-1-yl)-ethyl}phenoxy}-propyl)-amine; (2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-{3-[3-(2methylamino-ethyl)-phenoxyl-propyl}-amine; (2-Chloro-3-trifluoromethyl-benzyl)-(2,2diphenyl-ethyl)-[3-(3-{2-[(1H-imidazol-2-ylmethyl)-amino] -ethyl}-phenoxy)-propyl]-amine; (2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-{3-[3-(2-ethylamino-ethyl)phenoxy]-propyl}-amine; [3-(3-{2-[(5-Bromo-thiophen-2-ylmethyl)-amino}-ethyl}-phenoxy)propyl]-(2-chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-amine; (2-Chloro-3trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-[3-(3-{2-[(thiophen-2-ylmethyl)-amino]-ethyl}phenoxy)-propyl]-amine; (2-Chloro-3-trifluoromethyl-benzyl)-{3-[3-(2-dimethylaminoethyl)-phenoxy]-propyl}-(2,2-diphenyl-ethyl)-amine; (2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-{3-[3-(2-pyrrolidin-1-yl-ethyl)-phenoxy]-propyl}-amine; (2-Chloro-3trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-{3-[3-(2-morpholin-4-yl-ethyl)-phenoxy] propyl}-amine; (2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-{(R)-1-methyl-3-[3-(2-morpholin-4-yl-ethyl) -phenoxyl-propyl}-amine; (2-Chloro-3-trifluoromethyl-benzyl)-(2,2diphenyl-ethyl)-{(R)-2-methyl-3-[3-(2-morpholin-4-yl-ethyl) -phenoxy]-propyl}-amine; {3-[3-(2-Amino-ethyl)-phenoxy]-propyl}-(2-chloro-3-trifluoromethyl-benzyl)-(2,2-diphenylethyl)-amine; [2-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}phenyl)-ethyl]-isopropyl-amine; [2-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-diphenylethylamino]-propoxy}-phenyl)-ethyl]-propyl-amine; 2-[2-(3-{3-[(2-chloro-3-trifluoromethylbenzyl)-diphenylethyl-amino]-propoxy}-phenyl)-ethylamino]-ethanol; (2-Chloro-3trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-[3-(3-{2-[(1-methyl-1H-imidazol-2-ylmethyl)amino]-ethyl}-phenoxy)-propyl]-amine; (2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenylethyl)-{3-[3-(2-thiomorpholin-4-yl-ethyl)-phenoxy] -propyl}-amine; [2-(3-{3-[(2-chloro-3trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-phenyl)-ethylamino]-acetic acid; [2-

Group Art Unit No.: 1624

(3-{(R)-3-[(2-chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-butoxy}-phenyl)ethylamino]-acetic acid; {[2-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-diphenylethylamino]-propoxy}-phenyl)-ethyl]-methyl-amino}-acetic acid; 2-[2-(3-{3-[(2-chloro-3trifluoromethyl-benzyl)-diphenylethyl-aminol-propoxy}-phenyl)-ethylaminol-2-methylpropionic acid; (S)-2-[2-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]propoxy}-phenyl)-ethylamino]-propionic acid; (R)-1-[2-(3-{3-[(2-chloro-3-trifluoromethylbenzyl)-diphenylethyl-amino[-propoxy}-phenyl)-ethyl]-pyrrolidine-2-carboxylic acid; (S)-1-[2-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-phenyl)-ethyl]pyrrolidine-2-carboxylic acid; [2-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-diphenylethylamino]-propoxy}-phenyl)-ethyl]-pyrimidin-2-yl-amine; (2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-[3-(3-morpholin-4-yl-phenoxy)-propyl]-amine; (2-Chloro-3trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-[3-(3-piperidin-1-yl-phenoxy)-propyl]-amine; (3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-phenyl)-diethylamine; (2-Chloro-3-trifluoromethyl-benzyl)-{3-[3-(2,5-dimethyl-pyrrol-1-yl)-phenoxy]propyl}-(2,2-diphenyl-ethyl)-amine; (2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenylethyl)-[3-(3-piperazin-1-yl-phenoxy)-propyl]-amine; (2-Chloro-3-trifluoromethyl-benzyl)-((S)-2-phenyl-propyl)-[3-(3-piperazin-1-yl-phenoxy)-propyl]-amine; (2-Chloro-3trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-[(R)-2-methyl-3-(3-piperazin-1-yl-phenoxy)propyl]-amine; (2-Chloro-3-trifluoromethyl-benzyl)-isobutyl-[3-(3-piperazin-1-yl-phenoxy)propyl]-amine; [4-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]propoxy}-phenyl)-piperazin-1-yl]-acetic acid; [4-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-((S)-2-phenyl-propyl)-amino]-propoxy}-phenyl)-piperazin-1-yl]-acetic acid; [4-(3-{(R)-[(2chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-methyl-propoxy}-phenyl)-piperazin-1-yl]-acetic acid; [4-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-isobutyl-amino]-propoxy}phenyl)-piperazin-1-yll-acetic acid; (2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-{3-[3-(4-methyl-piperazin-1-yl)-phenoxy]-propyl}-amine; (2-Chloro-3-trifluoromethylbenzyl)-(2,2-diphenyl-ethyl)-[3-(3-pyrrolidin-1-yl-phenoxy)-propyl]-amine; (3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-phenylamino)-acetic acid; [(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-phenyl)-N-methylamino]-acetic acid; N-(2,2-Diphenylethyl)-N-(2-chloro-3-trifluoromethylbenzyl)-3-[3-(2methyl-2-aminopropyl)phenoxy|propylamine; N-(2,2-Diphenylethyl)-N-(2-chloro-3trifluoromethylbenzyl)-3-(3-[2-hydroxymethyl]phenoxy)propylamine; N-(2,2-Diphenylethyl)-

Group Art Unit No.: 1624

N-(2-chloro-3-trifluoromethylbenzyl)-3-(3-[2-hydroxy-2-methylpropyl]phenoxy)propylamine; N-(2,2-Diphenylethyl)-N-(2-chloro-3-trifluoromethylbenzyl)-3-(3-Nmethylsulfonamidophenoxy)propylamine; N-(2-[2-Chlorophenyl]-propyl)-N-(2-chloro-3trifluoromethylbenzyl)-3-(3-carboxymethylenephenoxy)propylamine; N-(2-[3-Chlorophenyl]propyl)-N-(2-chloro-3-trifluoromethylbenzyl)-3-(3-carboxymethylenephenoxy)propylamine; N-(2-[4-Chlorophenyl]-propyl)-N-(2-chloro-3-trifluoromethylbenzyl)-3-(3carboxymethylenephenoxy)propylamine; N-(2-[2-Methoxyphenyl]-propyl)-N-(2-chloro-3trifluoromethylbenzyl)-3-(3-carboxymethylenephenoxy)propylamine; N-(2-[4-Methoxyphenyl]-propyl)-N-(2-chloro-3-trifluoromethylbenzyl)-3-(3carboxymethylenephenoxy)propylamine; N-(2-Phenyl-4-methylpentyl)-N-(2-chloro-3trifluoromethylbenzyl)-3-(3-carboxymethylenephenoxy)propylamine; N-(2-Phenylbutyl)-N-(2-chloro-3-trifluoromethylbenzyl)-3-(3-carboxymethylenephenoxy)propylamine; N-(2-[2-Methyl-2-phenyl]propyl)-N-(2-chloro-3-trifluoromethylbenzyl)-3-(3carboxymethylenephenoxy)propylamine; N-(2-Phenyl-3-methylbutyl)-N-(2-chloro-3trifluoromethylbenzyl)-3-(3-carboxymethylenephenoxy)propylamine; N-(2-Phenylhexyl)-N-(2-chloro-3-trifluoromethylbenzyl)-3-(3-carboxymethylenephenoxy)propylamine; N-(2-Phenyl-3-butynyl)-N-(2-chloro-3-trifluoromethylbenzyl)-3-(3carboxymethylenephenoxy)propylamine; (S)-N-(2-Phenyl-2-methoxyethyl)-N-(2-chloro-3trifluoromethylbenzyl)-3-(3-carboxymethylenephenoxy)propylamine; (R)-N-(2-Phenyl-2-methoxyethyl)-N-(2-chloro-3-trifluoromethylbenzyl)-3-(3carboxymethylenephenoxy)propylamine; (R)-N-(2-Phenyl-2-methoxyethyl)-N-(2-chloro-3-Chloro-3-(trifluoromethyl)benzyl](2-methyl-propyl)amino]-propoxy}-phenyl)acetic acid; 1-(3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-phenyl)cyclobutanecarboxylic acid; 1-(3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-diphenylethylaminol-propoxy}-phenyl)-cyclopentanecarboxylic acid; 1-(3-{3-[(2-Chloro-3trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-amino]-propoxy}-phenyl)cyclopropanecarboxylic acid;

and a pharmaceutically acceptable salt or hydrate thereof.

Group Art Unit No.: 1624

106. (New): The compound according to claim 49, selected from:

2-(3-{3-[[2-chloro-3-(trifluoromethyl)benzyl](2,2-

dephenylethyl)amino]propoxy}phenyl)-ethanol,

 $(2-chloro-3-trifluoromethyl-benzyl)-(2,2-diphenylethyl)-\{3-[3-(1,2,4-triazol-3-ylmethyl)-phenoxy]-propyl\}-amine,$ 

 $(2-chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-\{3-[3-(1,2,3,4-tetrazol-5-ylmethyl)-phenoxy]-propyl\}-amine,$ 

 $(2-chloro-3-trifluoromethyl-benzyl)-(2-cyclohexyl-2-phenyl-ethyl)-\{3-[3-(1,2,3,4-tetrazol-5-ylmethyl)-phenoxy]-propyl\}-amine,$ 

 $2-(3-\{3-[[2-chloro-3-(trifluoromethyl)benzyl]-benzylamino] propoxy\}-phenyl) acetic acid,\\$ 

2-(3-{3-[[2-chloro-3-(trifluoromethyl)-benzyl]phenethylamino]propoxy}-phenyl)acetic acid,

2-(3-{3-[[2-chloro-3-(trifluoromethyl)benzyl](2-hydroxy-2-phenyl-ethyl)amino]propoxy}-phenyl)acetic acid,

2-(3-{3-[[2-chloro-3-(trifluoromethyl)benzyl](2-acetoxy-2-phenyl-ethyl)amino]propoxy}-phenyl)acetic acid,

2-(3-{3-[[2-chloro-3-(trifluoromethyl)benzyl](2-phenoxy-2-phenyl-ethyl)amino]propoxy}-phenyl)acetic acid,

(3-{3-[(2-acetoxy-2-phenyl-ethyl)-(2-chloro-3-trifluoromethyl-benzyl)-amino}-propoxy}-phenyl)-acetic acid methyl ester,

benzoic acid 2-[3-(3-methoxycarbonylmethyl-phenoxy){2-chloro-3-(trifluoromethyl)benzyl}propylamino]-1-phenyl ethyl ester,

(3-{4-[(2-chloro-3-(trifluoromethyl)benzyl)-(2,2-diphenylethyl)-amino]butyl}phenyl)-acetic acid,

2-(3-{3-[[2-chloro-3-(trifluoromethyl)benzyl](2,2-dephenylethyl)amino]propoxy}phenyl)-ethanol,

 $(2-chloro-3-trifluoromethyl-benzyl)-(2,2-diphenylethyl)-{3-[3-(1,2,4-triazol-3-ylmethyl)-phenoxy]-propyl}-amine,$ 

 $(2-chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-\{3-[3-(1,2,3,4-tetrazol-5-ylmethyl)-phenoxy]-propyl\}-amine,\\$ 

Group Art Unit No.: 1624

furan-2-carboxylic acid N-(3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-2,2-

 $diphenylethyl-amino]-propoxy\}-phenyl)-amide,\\$ 

2-(3-{3-[[2-chloro-3-(trifluoromethyl)benzyl](2-acetoxy-2-phenyl-ethyl)amino]propoxy}-phenyl)acetic acid,

(3-{3-[(2-acetoxy-2-phenyl-ethyl)-(2-chloro-3-trifluoromethyl-benzyl)-amino]-propoxy}-phenyl)-acetic acid methyl ester,

(3-{4-[(2-chloro-3-(trifluoromethyl)benzyl)-(2,2-diphenylethyl)-amino]butyl}phenyl)-acetic acid,

1-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-phenyl)-cyclobutanecarboxylic acid,

N-(2,2-diphenylethyl)-N-(2-chloro-3-trifluoromethylbenzyl)-3-(3-[2-hydroxy-2-methylpropyl]phenoxy) propylamine,

 $(2-chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-[3-(3-\{2-[(1H-imidazol-2-ylmethyl)-amino]-ethyl\}-phenoxy)-propyl]-amine,\\$ 

N-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-2,2-diphenylethyl-amino]-propoxy}-phenyl)-methanesulfonamide,

N-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-2,2-diphenylethyl-amino]-propoxy}-phenyl)-N-methyl-amine,

[2-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-phenyl)-ethylamino]-acetic acid,

N-(2-[3-chlorophenyl]-propyl)-N-(2-chloro-3-trifluoromethylbenzyl)-3-(3-carboxymethylenephenoxy) propylamine,

[4-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-phenyl)-piperazin-1-yl]-acetic acid,

 $(2-chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-\{3-[3-(4-methyl-piperazin-1-yl)-phenoxy]-propyl\}-amine,\\$ 

[1-(3-{3-[(2-chloro-3-(trifluoromethyl)-benzyl)-(2,2-diphenylethyl)-amino]-propoxy}-phenyl-piperidine-4-carboxylic acid,

and a pharmaceutically acceptable salt or hydrate thereof.

Group Art Unit No.: 1624

- 107. (New): The compound according to claim 49, selected from:
- $(S)-(2-chloro-3-trifluoromethyl-benzyl)-(2-phenyl-propyl)-\{3-[3-(1,2,3,4-tetrazol-3-ylmethyl)-phenoxy]-propyl\}-amine,$
- $(R)-(2-chloro-3-trifluoromethyl-benzyl)-(2-phenyl-propyl)-\{3-[3-(1,2,3,4-tetrazol-3-ylmethyl)-phenoxy]-propyl\}-amine,$
- (S)-2-(3-{3-[[2-chloro-3-(trifluoromethyl)benzyl](2-phenyl-propyl)amino]propoxy}-phenyl)acetic acid,
- (R)-2-(3-{3-[[2-chloro-3-(trifluoromethyl)benzyl](2-phenyl-propyl)amino]propoxy}-phenyl)acetic acid,
- (R)-1-[2-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-phenyl)-ethyl]-pyrrolidine-2-carboxylic acid,
- (2-chloro-3-trifluoromethyl-benzyl)-{3-[3-(2-morpholin-4-yl-ethyl)-phenoxy]-propyl}-((S)-2-phenyl-propyl amine,
- 2-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-((S)-2-phenyl-propyl)-amino]-propoxy}-phenyl)-2-methyl-propionic acid,
- $(3-\{(R)-3-[(2-chloro-3-trifluoromethyl-benzyl)-((S)-2-phenyl-propyl)-amino]-butoxy\}-phenyl)-acetic acid,\\$
- [4-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-((S)-2-phenyl-propyl)-amino]-propoxy}-phenyl)-piperazin-1-yl]-acetic acid,
- [4-(3-{(R)-[(2-chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-methyl-propoxy}-phenyl)-piperazin-1-yl]-acetic acid,

and a pharmaceutically acceptable salt or hydrate thereof.